Potential role of ubiquinone (coenzyme Q10) in pediatric cardiomyopathy
| Autor: | Raj K. Chopra, Hemmi N. Bhagavan |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
medicine.medical_specialty
Heart disease Pediatric cardiomyopathy Ubiquinone Coenzymes Cardiomyopathy Critical Care and Intensive Care Medicine Bioinformatics chemistry.chemical_compound Internal medicine medicine Humans Coenzyme Q10 Nutrition and Dietetics business.industry Infant Dilated cardiomyopathy medicine.disease Transplantation chemistry Heart failure Dietary Supplements Cardiology Myocardial disease Cardiomyopathies business |
| Zdroj: | Clinical Nutrition. 24:331-338 |
| ISSN: | 0261-5614 |
| DOI: | 10.1016/j.clnu.2004.12.005 |
| Popis: | Pediatric cardiomyopathy (PCM) represents a group of rare and heterogeneous disorders that often results in death. While there is a large body of literature on adult cardiomyopathy, all of the information is not necessarily relevant to children with PCM. About 40% of children who present with symptomatic cardiomyopathy are reported to receive a heart transplant or die within the first two years of life. In spite of some of the advances in the management of PCM, the data shows that the time to transplantation or death has not improved during the past 35 years. Coenzyme Q10 is a vitamin-like nutrient that has a fundamental role in mitochondrial function, especially as it relates to the production of energy (ATP) and also as an antioxidant. Based upon the biochemical rationale and a large body of data on patients with adult cardiomyopathy, heart failure, and mitochondrial diseases with heart involvement, a role for coenzyme Q10 therapy in PCM patients is indicated, and preliminary results are promising. Additional studies on the potential usefulness of coenzyme Q10 supplementation as an adjunct to conventional therapy in PCM, particularly in children with dilated cardiomyopathy, are therefore warranted. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect